Clinical Trial Update: Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in breast cancer patients, with the study status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 68-GaNOTA-Anti-HER2 VHH1 (68-GaNOTA-Anti-HER2 VHH1)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Metastatic Breast Carcinoma, Locally Advanced Breast Cancer | Phase 2 | Status: UNKNOWN